← Back to Screener
Surrozen, Inc. Warrant (SRZNW)
Price$0.02
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-27.53%
Price vs S&P 500 (4W)-14.06%
VGM Score31.35
All Metrics
Price vs S&P 500 (YTD)-36.64%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.02M
52-Week High$1.21
26-Week Price Return-11.60%
13-Week Price Return-13.51%
3-Month Return Std Dev297.24%
Year-to-Date Return-20.00%
5-Day Price Return-17.95%
Month-to-Date Return-14.89%
Price vs S&P 500 (13W)-23.26%
Beta0.78x
52-Week Low$0.00
mGradeD
vgmGradeD
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SRZNWSurrozen, Inc. Warrant | — | — | D | $0.02 |
| AMGNAmgen Inc | C | C | C | $338.22 |
| GILDGilead Sciences Inc | C | B | C | $128.99 |
| ARGXargenx SE American Depositary Shares | D | A | B | $813.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $155.99 |
| BIIBBiogen Inc. Common Stock | B | D | C | $195.96 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.45 |
| MRNAModerna, Inc. Common Stock | C | B | C | $49.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $165.11 |
| EXELExelixis Inc | C | B | B | $51.60 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $301.82 |
About
Surrozen Inc is a clinical-stage biotechnology company developing therapies that modulate the Wnt pathway to promote tissue repair across multiple organ systems. The company is advancing a pipeline of drug candidates, including SZN-1326, SZN-413, and SZN-043, each targeting distinct mechanisms to maximize therapeutic potential. Surrozen's focused approach to Wnt pathway biology aims to address unmet clinical needs in regenerative medicine and tissue homeostasis.